Physician profile
Leon Ravin
NPI 1760417364
$106,476.85
in general payments reported to CMS, 2019-2025
16 companies · $1,772 in 2025
The $1,772 reported for 2025 was more than what 88% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $43K · 2020: $8,931 · 2021: $10K · 2022: $26K · 2023: $13K · 2024: $2,914 · 2025: $1,772.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $11K · Food and Beverage: $5,988 · Travel and Lodging: $327 · Education: $6.41.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $11,347.50 |
| Food and Beverage | $5,988.22 |
| Travel and Lodging | $327.49 |
| Education | $6.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $43,857.79 | 2019-2025 | Lybalvi, Aristada |
| Janssen Pharmaceuticals, INC | $35,978.84 | 2019-2025 | Invega Sustenna, Spravato, Invega |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $10,203.61 | 2020-2023 | |
| Bioxcel Therapeutics, INC. | $6,066.34 | 2023-2024 | Igalmi |
| Otsuka America Pharmaceutical, INC. | $3,765.73 | 2019-2025 | Abilify Maintena, Abilify Asimtufii |
| Neurocrine Biosciences, INC. | $2,249.63 | 2019-2025 | Ingrezza |
| Teva Pharmaceuticals USA, INC. | $1,150.48 | 2019-2025 | Uzedy |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $893.96 | 2021-2025 | Caplyta |
| Sunovion Pharmaceuticals INC. | $742.40 | 2019-2021 | |
| Janssen Scientific Affairs, LLC | $342.05 | 2025 | Invega Sustenna |
| E.R. Squibb & Sons, L.L.C. | $306.92 | 2024-2025 | Cobenfy |
| Indivior INC. | $273.75 | 2022-2024 | Perseris |
| Abbvie INC. | $251.11 | 2023-2024 | |
| Tris Pharma INC | $219.65 | 2025 | Onyda Xr |
| Vanda Pharmaceuticals INC. | $157.13 | 2019-2022 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $17.46 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Leon Ravin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.